[go: up one dir, main page]

WO2004012765A1 - Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese - Google Patents

Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese Download PDF

Info

Publication number
WO2004012765A1
WO2004012765A1 PCT/RU2002/000366 RU0200366W WO2004012765A1 WO 2004012765 A1 WO2004012765 A1 WO 2004012765A1 RU 0200366 W RU0200366 W RU 0200366W WO 2004012765 A1 WO2004012765 A1 WO 2004012765A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
anτiτel
πuτem
erythropoietin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2002/000366
Other languages
English (en)
Russian (ru)
Inventor
Oleg Iliich Epshtein
Evgeny Danilovich Goldberg
Alexandr Mikhailovich Dygay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002325432A priority Critical patent/AU2002325432A1/en
Priority to PCT/RU2002/000366 priority patent/WO2004012765A1/fr
Publication of WO2004012765A1 publication Critical patent/WO2004012765A1/fr
Priority to IL16627005A priority patent/IL166270A0/xx
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • Izves ⁇ en s ⁇ s ⁇ b treatment ⁇ a ⁇ l ⁇ giches ⁇ g ⁇ Sind ⁇ ma, svyazann ⁇ g ⁇ with na ⁇ usheniem ⁇ ve ⁇ v ⁇ eniya, ⁇ u ⁇ em administration ⁇ ganizm ⁇ e ⁇ mbinan ⁇ n ⁇ g ⁇ chel ⁇ veches ⁇ g ⁇ e ⁇ i ⁇ e ⁇ ina (see., Na ⁇ ime ⁇ , ⁇ egis ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v ⁇ ssii "Entsi ⁇ l ⁇ ediya le ⁇ a ⁇ s ⁇ v" edition 7, ⁇ s ⁇ va, ⁇ LS, 2000, s.789).
  • human or heterologous eritrogen alpha, beta or omega are used, including recombinant or genetically engineered.
  • the predominant use of the mixture is various, preferably commercially available, homogenous dilutions.
  • the medicinal product is prepared by the following process.
  • the resulting immune antibodies cleans by the method of affinity chromatography with protein ⁇ .
  • the current processing in the process of reducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
  • mice line S ⁇ / Saas ⁇ n ⁇ ln ⁇ y and ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ ⁇ edva ⁇ i ⁇ eln ⁇ vv ⁇ dili ad ⁇ iamitsin in d ⁇ ze 6 mg / ⁇ g ⁇ dn ⁇ a ⁇ n ⁇ vnu ⁇ ib ⁇ yushinn ⁇ .
  • the lively commercial group received an appropriate consumer (distilled water) in an equivalent volume for the same purpose.
  • C 3 ⁇ 10th and 12th su ⁇ i e ⁇ s ⁇ e ⁇ imen ⁇ a zhiv ⁇ ny ⁇ ume ⁇ schvlyali me ⁇ d ⁇ m tse ⁇ vi ⁇ aln ⁇ y disl ⁇ atsii ⁇ zv ⁇ n ⁇ chni ⁇ a, ⁇ edelyali ⁇ bschuyu ⁇ le ⁇ chn ⁇ s ⁇ ⁇ s ⁇ n ⁇ g ⁇ m ⁇ zga ( ⁇ ), ⁇ bschee ⁇ liches ⁇ v ⁇ ley ⁇ tsi ⁇ v ( ⁇ L) ⁇ e ⁇ i ⁇ ul ⁇ tsi ⁇ v and e ⁇ i ⁇ tsi ⁇ v in ⁇ e ⁇ i ⁇ e ⁇ iches ⁇ y ⁇ vi.
  • the corresponding myeloma and the hematogram were calculated.
  • SIGNIFICANT FOX (DR. 26) Table 1.
  • mice * ** ***. The differences in intact mice are available; $, $$ differences are available, respectively, ⁇ ⁇ 0.05; 0.01; 0.001

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une préparation médicinale à base d'anticorps monoclonaux comprend une forme activée de doses extrêmement faibles d'anticorps monoclonaux, polyclonaux ou naturels de l'érythropoeïétine, obtenue par la dilution multiple et continue et par l'application d'un facteur externe, principalement au moyen d'une technique homéopathique. Pour obtenir ces anticorps on utilise une érythropoeïétine alpha, bêta ou oméga, y compris celle recombinée ou obtenue par génie génétique; on utilise à cet effet un mélange de dilutions homéopathiques, de préférence centésimales. Le procédé de traitement du syndrome pathologique dû à une perturbation de l'hématopoïèse et principalement de l'érythropoïèse consiste à utiliser des formes activées de doses extrêmement faibles d'anticorps monoclonaux, polyclonaux ou naturels de l'érythropoeïétine, obtenue par la dilution multiple et continue et par l'application d'un facteur externe.
PCT/RU2002/000366 2002-08-02 2002-08-02 Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese Ceased WO2004012765A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002325432A AU2002325432A1 (en) 2002-08-02 2002-08-02 Medicinal agent and method for curing pathological syndrome associated to hemodiscrasia
PCT/RU2002/000366 WO2004012765A1 (fr) 2002-08-02 2002-08-02 Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese
IL16627005A IL166270A0 (en) 2002-08-02 2005-01-06 A pharmaceutical composition containing an activated form of ultra small doses of antibodies to the endothelial nitric acid synthase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2002/000366 WO2004012765A1 (fr) 2002-08-02 2002-08-02 Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese

Publications (1)

Publication Number Publication Date
WO2004012765A1 true WO2004012765A1 (fr) 2004-02-12

Family

ID=31492974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000366 Ceased WO2004012765A1 (fr) 2002-08-02 2002-08-02 Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese

Country Status (3)

Country Link
AU (1) AU2002325432A1 (fr)
IL (1) IL166270A0 (fr)
WO (1) WO2004012765A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9308259B2 (en) 2006-06-06 2016-04-12 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2070338C1 (ru) * 1992-03-03 1996-12-10 Сергей Владимирович Панько Способ пересадки костного мозга в область кости в эксперименте
RU95119854A (ru) * 1993-03-31 1998-01-10 Про-Ньюрон, Инк. Ингибитор пролиферации стволовых клеток и его использование
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
WO2001097842A1 (fr) * 2000-06-20 2001-12-27 Oleg Iliich Epshtein Procede de traitement d'un syndrome pathologique et produit medicamenteux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431473T2 (de) * 1993-03-31 2003-08-07 Pro-Neuron, Inc. Inhibitor der stammzellproliferation und seine verwendung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2070338C1 (ru) * 1992-03-03 1996-12-10 Сергей Владимирович Панько Способ пересадки костного мозга в область кости в эксперименте
RU95119854A (ru) * 1993-03-31 1998-01-10 Про-Ньюрон, Инк. Ингибитор пролиферации стволовых клеток и его использование
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
WO2001097842A1 (fr) * 2000-06-20 2001-12-27 Oleg Iliich Epshtein Procede de traitement d'un syndrome pathologique et produit medicamenteux

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8871203B2 (en) 2000-06-20 2014-10-28 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8894995B2 (en) 2000-06-20 2014-11-25 Oleg Iliich Epshtein Method of treating a disorder or condition of viral etiology
US9200081B2 (en) 2000-06-20 2015-12-01 Oleg Iliich Epshtein Method for administering homeopathically potentiated antibodies against mediator of inflammation
US9228024B2 (en) 2000-06-20 2016-01-05 Oleg Iliich Epshtein Method of treating hypertension disorder and a pharmaceutical agent
US9303090B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9303091B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating disorders of the cardiovascular system and a pharmaceutical agent
US9382332B2 (en) 2000-06-20 2016-07-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US9308259B2 (en) 2006-06-06 2016-04-12 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Also Published As

Publication number Publication date
AU2002325432A1 (en) 2004-02-23
IL166270A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
WO2003055519A1 (fr) Agent pharmaceutique et methode de traitement de maladies s'accompagnant de troubles du tonus vasculaire
WO2005000350A1 (fr) Medicament et methode de traitement d'un syndrome pathologique
WO2004012764A1 (fr) Medicament et procede de traitement des maladies de la prostate
AU2011287292B2 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
US20010018053A1 (en) Methods for treating disease states comprising administration of low levels of antibodies
JPH09509411A (ja) 上昇したインターロイキン−６血清レベルを有する疾病を治療するための医薬としてのアンチ−ｔｎｆ抗体の使用
MX2013000542A (es) Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.
WO2004012767A1 (fr) Preparation medicinale et procede de traitement de dyserections
RU2187334C2 (ru) Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
CN103097414A (zh) 膜联蛋白1抗体
EA029399B1 (ru) Комбинированная фармацевтическая композиция для лечения болезни альцгеймера и способ лечения болезни альцгеймера
WO2005039636A1 (fr) Produit pour potentialiser les effets curatifs et intensifier l'action d'un medicament
WO2003055518A1 (fr) Procede de traitement d'etats immuno-pathologiques et medicament correspondant
RU2192882C1 (ru) Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
WO2004012765A1 (fr) Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese
WO2003077946A1 (fr) Agent pharmaceutique et methode de traitement d'un syndrome pathologique associe a hemodyscrasia
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
US20070232547A1 (en) Two synthetic peptides for treatment and prevention of cancers
WO2003037372A1 (fr) Procede de retablissement de processus physiologiques perturbes et medicament
Herzberger et al. Homeopathic treatment of infections of various origins: a prospective study
WO2003055517A1 (fr) Procede de correction de la reponse immunitaire et medicament
RU2500426C2 (ru) Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1, и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1
RU2209084C1 (ru) Лекарственное средство и способ лечения депрессивных расстройств
CN115417930A (zh) 重组抗体及其应用
RU2519695C2 (ru) Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 166270

Country of ref document: IL

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP